Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2A type 3 (also called H2A clustered histone 25, HIST3H2A, or H2AW) is one of numerous H2A histone variants encoded in clustered gene arrays in the genome[3][5]. As a core component of nucleosomes, it contributes to DNA packaging and chromatin structure. While some H2A variants participate in specialized processes—such as X-chromosome inactivation or DNA damage response—this variant itself is not commonly associated with direct therapeutic targeting or selective modulation. Functional diversity among H2A family members arises from differences at the N- and C-termini, affecting nucleosome stability, gene regulation, and disease relevance[1][4].
Not applicable for direct drug action; general mechanisms include altering post-translational modifications or chromatin accessibility[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2A type 3 (HIST3H2A).